Hoth Therapeutics, Inc. has entered into a sponsored research agreement with GW to explore the potential use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.
A team at the GW Cancer Center found that the deubiquitinating enzyme USP15 is a potential biomarker for treatments of breast and pancreatic cancers.
TESTS SHOW BP1 POSITIVE FOR 80% OF WOMEN WITH BREAST CANCER, 70% of men with prostate cancer, 63% of acute myeloid leukemia patients, 78% with non-small cell lung cancer, 47% with ovarian cancer.
BERG ALSO TO ADDRESS ROME WORLD CONGRESS ON SEPARATION SCIENCE (April 16-17)
Researchers from GW, FDA, and industry leaders published in PLOS Biology, describing a standardized communication method for researchers performing high-throughput sequencing called BioCompute.
Rong Li, PhD, will serve as chair of the Department of Biochemistry and Molecular Medicine at the GW School of Medicine and Health Sciences.